Swiss skincare firm Galderma, Brazilian cosmetics group Natura, and beauty giant L'Oreal are testing treatments for consumers worried about facial sagging and volume loss, looking to capitalise on a growing market tied to the boom in obesity drugs.

The ‌companies are targeting concerns known as "Ozempic face," a term that emerged as the diabetes drug became widely associated with weight loss. Experts say the loss of facial volume is linked to rapid weight loss rather than GLP-1 drugs themselves.

This is the third story in a five-part Reuters series on how weight-loss drugs are changing the way people shop and eat, and how companies are responding to the trend.

Prince Harry has said he hoped to reconcile with King Charles and the rest of his family with whom he fell out when he moved to the United States six years ‌ago.

The king's younger son caused a rupture in the British royal family when he and his wife Meghan quit royal duties and moved to California in 2020 from where they were highly critical of the institution.

But in an interview with GQ magazine, Harry, who recently relocated back to Britain with Meghan and their two children, said he wanted to patch ⁠things up.